Immunic, Inc.
IMUX
$1.12
-$0.03-2.61%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.03% | 15.42% | 16.68% | 19.99% | 13.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.62% | 9.15% | -8.82% | -12.37% | -4.01% |
| Operating Income | -9.62% | -9.15% | 8.82% | 12.37% | 4.01% |
| Income Before Tax | -16.70% | -7.02% | 10.91% | -17.06% | 61.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.70% | -7.02% | 10.91% | -17.06% | 61.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.70% | -7.02% | 10.91% | -17.06% | 61.80% |
| EBIT | -9.62% | -9.15% | 8.82% | 12.37% | 4.01% |
| EBITDA | -9.58% | -9.13% | 8.86% | 12.36% | 4.03% |
| EPS Basic | 48.32% | 52.90% | 60.91% | 47.48% | 67.19% |
| Normalized Basic EPS | 48.33% | 52.90% | 60.93% | 55.99% | 21.17% |
| EPS Diluted | 48.32% | 52.90% | 60.91% | 47.48% | 67.19% |
| Normalized Diluted EPS | 48.33% | 52.90% | 60.93% | 55.99% | 21.17% |
| Average Basic Shares Outstanding | 125.80% | 127.20% | 127.92% | 122.83% | 16.42% |
| Average Diluted Shares Outstanding | 125.80% | 127.20% | 127.92% | 122.83% | 16.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |